Northpointe Capital LLC cut its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 10.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,375 shares of the medical research company’s stock after selling 1,884 shares during the period. Northpointe Capital LLC’s holdings in Thermo Fisher Scientific were worth $2,909,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Thermo Fisher Scientific by 2.4% in the second quarter. Vanguard Group Inc. now owns 26,600,394 shares of the medical research company’s stock valued at $4,640,970,000 after acquiring an additional 629,093 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Thermo Fisher Scientific by 1.6% in the second quarter. BlackRock Inc. now owns 23,355,469 shares of the medical research company’s stock valued at $4,074,828,000 after acquiring an additional 366,584 shares in the last quarter. Capital Research Global Investors boosted its holdings in shares of Thermo Fisher Scientific by 29.8% in the second quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock valued at $3,019,185,000 after acquiring an additional 3,973,136 shares in the last quarter. State Street Corp boosted its holdings in shares of Thermo Fisher Scientific by 1.0% in the first quarter. State Street Corp now owns 16,085,954 shares of the medical research company’s stock valued at $2,470,802,000 after acquiring an additional 164,367 shares in the last quarter. Finally, Capital World Investors boosted its holdings in shares of Thermo Fisher Scientific by 6.1% in the second quarter. Capital World Investors now owns 11,759,734 shares of the medical research company’s stock valued at $2,051,721,000 after acquiring an additional 671,637 shares in the last quarter. Institutional investors and hedge funds own 83.78% of the company’s stock.

A number of brokerages recently weighed in on TMO. Jefferies Group LLC restated a “hold” rating and set a $195.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, September 28th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $197.00 target price for the company in a report on Tuesday, August 1st. BidaskClub cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. The Goldman Sachs Group, Inc. began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, September 26th. They set a “buy” rating and a $225.00 target price for the company. Finally, Barclays PLC restated an “overweight” rating and set a $215.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $205.71.

In other Thermo Fisher Scientific news, VP Seth H. Hoogasian sold 4,140 shares of the stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $177.80, for a total value of $736,092.00. Following the completion of the sale, the vice president now owns 25,518 shares in the company, valued at approximately $4,537,100.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director C Martin Harris sold 360 shares of the stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $180.97, for a total transaction of $65,149.20. Following the completion of the sale, the director now owns 5,312 shares of the company’s stock, valued at approximately $961,312.64. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,420 shares of company stock valued at $1,888,977. 0.49% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/17/thermo-fisher-scientific-inc-tmo-stake-lessened-by-northpointe-capital-llc.html.

Shares of Thermo Fisher Scientific Inc (NYSE TMO) opened at $190.61 on Friday. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. The company has a market cap of $75,591.64, a P/E ratio of 20.72, a P/E/G ratio of 1.73 and a beta of 1.08. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $201.20.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.24 by $0.07. The business had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm’s quarterly revenue was up 13.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.03 EPS. research analysts forecast that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be given a $0.15 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.19%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.